Search
Find exactly what you’re looking for.
Search

Section
Topics
Industry
Service
Insights
Location
Showing 21-35 of 35 results

The Fundamentals of Arbitration Are you dealing with a dispute and debating whether to resolve it through arbitration pursuant to an arbitration provision in the subject agreement? Are you considering adding an arbitration provision to your standard contracts? This webinar will provide you with the...
​The FTC has announced the annual updates to the Hart-Scott-Rodino (“HSR”) size thresholds, fees and the daily penalty for HSR violations. The updated thresholds and fees were published in the Federal Register on January 26, 2023 and will take effect on February 27, 2023. See Federal Register...

Recent Cases Interpreting the Federal Arbitration Act: Badgerow v. Walters & More! Litigation Associate Stephanie Denker will join a panel and discuss important decisions impacting arbitration waivers, petitions to confirm arbitral awards under 9 U.S.C. §9 and petitions to vacate arbitral awards...
LATEST UPDATE The FTC has voted to extend the public comment period on its proposed rule to ban employers from imposing non-competes on their workers, and will now be accepting comments on the proposed rule until April 19, 2023. Comments can still be submitted in either writing or online using the...

Saul Ewing is a proud sponsor of the M&A East Conference held by the Philadelphia Chapter of the Association of Corporate Growth. M&A East attracts top strategic and financial dealmakers as well as leading middle market advisors and provides an environment for valuable networking. The conference...

Kathryn Doyle, Partner at Saul Ewing LLP, will be presenting at the NACUA Annual Meeting, June 26-29, 2022, in Pittsburgh. She will be speaking on June 28, 9:15-10:30 a.m., on the topic "You Thought You Owned It, They Might Have Stolen It, and a Medley of Inventor Kerfuffles”. Joining Kathryn will...

Washington, D.C., November 24, 2021 – Saul Ewing LLP served as counsel to Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the successful completion today of its previously announced $450 million acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The acquisition strengthens Supernus'...
For More Information
Contact us